Press Release | CEO MESSAGE: COVID-19 UPDATE

CEO MESSAGE: COVID-19 UPDATE

Press Contact: Matt Smith
ProTrials Research, Inc.
650.386.7712
MSmith@protrials.com

San Jose, CA – March 26, 2020 –

ProTrials’ senior management has been monitoring the global COVID-19 pandemic with a focus to protect study patients and our employees, while ensuring business continuity with our sponsor partners. We are staying abreast of latest guidance from the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and other national health organizations.

We remain focused on providing support to our sponsors and study sites who are on the front line of healthcare and patient safety. Here are the latest updates on actions we are taking to mitigate risk while maintaining business continuity:

– Following governmental travel restrictions and advice for all regions where we operate to ensure safety of our staff and colleagues.

– Adhering to “stay at home” guidance by providing flexible work arrangements to ensure consistent project coverage. We remotely monitor all systems and have a core team rotating through our headquarters to ensure integrity of systems.

– Activating business continuity plans to ensure delivery of our project commitments. Study teams are working with clients and vendor partners to ensure deliverables are met, and proactively working together to develop solutions as needed (e.g., remote monitoring per SOP).

– Cooperating with study sites to ensure access to proper clinical care on-site or remotely, including creating contingency plans for availability of study related medication and supplies.

– Working with our sponsor partners to implement technologies that support virtual patient assessments and site management activities.

Our decisions have been and will continue to be guided by our commitment to deliver the best service and outcome to our customers while also maintaining concern for the well-being of the patients, the site staff, and our employees. We will continue to assess the evolving impact of the pandemic, and we recognize that your project may have unique considerations.

The clinical research community is uniquely positioned to help develop therapies as well as a vaccine. ProTrials has supported vaccine and infectious disease trials for 24 years and more than 70% of our clinical staff have related trial experience. We have managed vaccine trials focused on flu, HIV, meningitis, oncology, hepatitis B, smallpox, anthrax, among others, and are ready to support new trials focused on COVID-19.

Please reach out to us if we can be of assistance, we are here to help.

Jodi Andrews & Inger Arum

Founders and Co-CEOs

About ProTrials Research, Inc.

ProTrials Research, Inc., is a mid-sized full-service clinical research organization (CRO) headquartered in San Jose, CA, with clinical operations personnel located throughout North America and across the world. Since our launch in 1996 as a woman-owned business, we have been driven by a shared commitment to provide outstanding service to the clinical research industry. To this day, that commitment remains our guiding principle and is reflected in our high-repeat business rate. ProTrials works with sponsors in the pharmaceutical, biotechnology and medical device industries to deliver high-quality clinical operations services such as study management, investigative site monitoring, grant services, project and program management, biometrics including biostatistics, pharmacovigilance, and associated clinical development services. Our operations support expands into Europe, Asia-Pacific, and Latin American countries. To learn how ProTrials Research, Inc., can help advance your clinical trial success, please visit us at www.protrials.com or call 650.386.7712.